“Our decision to adopt digital pathology and chart our course with Proscia strongly reflects Altasciences’ guiding focus on ensuring our sponsors’ success,” said Dr. Wendell P. Davis, Vice President of Pathology.
LAVAL, Québec and PHILADELPHIA (PRWEB)
March 21, 2023
Proscia®, a leading provider of digital and computational pathology solutions, today announced that Altasciences, a forward-thinking contract research organization (CRO), has chosen Concentriq® for Research to help its sponsors get life-saving therapeutics to patients sooner. The CRO will deploy Proscia’s software platform to advance faster, more complete preclinical development decisions.
The average drug takes 10 to 15 years and costs $2.6 billion to bring to market.[1] Altasciences is enabling biopharmaceutical companies of all sizes to overcome these lengthy timelines and high costs through its proven approach to preclinical and clinical research and beyond. As pathology data factors heavily into research and development (R&D), the CRO recognized that digitizing its pathology workflows would open new opportunities to tap into this critical source of insight and drive powerful efficiencies.
“Our decision to adopt digital pathology and chart our course with Proscia strongly reflects Altasciences’ guiding focus on ensuring our sponsors’ success,” said Dr. Wendell P. Davis, Vice President of Pathology. “Concentriq for Research is the only platform that offers the robust feature set and scalability essential to meeting the evolving needs of our scientists and the biopharmaceutical organizations that we serve.”
Trusted by 14 of the top 20 pharmaceutical companies and leading CROs, Concentriq for Research is the modern pathology platform accelerating breakthroughs across the R&D value chain. Altasciences will initially deploy Concentriq for Research to unify massive volumes of study data and streamline collaboration among internal and external stakeholders, enabling its scientists to draw faster, more complete conclusions and increasingly work as an extension of sponsors’ teams. The CRO also plans to draw on the platform’s newly expanded capabilities for GLP compliant studies as well as leverage its world-class interoperability to unlock new insights with artificial intelligence (AI).
“Altasciences is an incredibly forward-thinking contract research organization that shares our commitment to innovation,” said David West, Proscia’s CEO. “We are humbled that its team has selected Concentriq for Research to drive its digital pathology operations and play a key role in helping its sponsors accelerate the introduction of life-saving drugs.”
To learn more about Altasciences’ comprehensive early phase drug development solutions, visit booth #633 at the 62nd Society of Toxicology Annual Meeting and ToxExpo, or attend their eight scientific poster and exhibitor-hosted sessions. Proscia is also giving live demonstrations of Concentriq for Research, including its newly announced features for preclinical R&D, at booth #636, and showcasing the expanded platform during a live webinar on May 3 at 11 AM EDT.
For a deeper dive into how digitizing its pathology operations with Concentriq for Research will provide value to sponsors worldwide, listen to Altasciences’ podcast.
About Altasciences
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
About Proscia
Proscia is a software company that is accelerating pathology’s digital transformation to change the way we understand diseases like cancer. Its Concentriq digital pathology platform and powerful AI applications are advancing the 150-year-old standard of research and diagnosis towards a data-driven discipline, unlocking new insights that accelerate discovery, improve patient outcomes, and fulfill the promise of precision care. Leading diagnostic laboratories and 14 of the top 20 pharmaceutical companies rely on Proscia’s software each day. For more information, visit proscia.com.
[1] Pharmaceutical Researchers and Manufacturers of America. (2021, September 30). Research & Development Policy Framework. PhRMA Org. Retrieved March 15, 2023, from https://phrma.org/policy-issues/Research-and-Development-Policy-Framework
Share article on social media or email: